← Back to Search

Cancer Vaccine

Rituxan + Idiotype Vaccine for Non-Hodgkin's Lymphoma

Phase 2

Waitlist Available

Research Sponsored by Favrille

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Performance status (ECOG) of 0, 1 or 2

Patients that are relapsed or refractory following chemotherapy

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is testing if a combination of drugs can help the body create an immunity response to a protein.

Who is the study for?

This trial is for adults over 18 with low-grade follicular B-cell lymphoma who have relapsed after chemotherapy or Rituxan treatment. They must have measurable disease, adequate organ function, and no serious non-cancer illnesses or uncontrolled infections. Pregnant women, those on immunosuppressants, HIV positive individuals, and patients with certain prior treatments are excluded.Check my eligibility

What is being tested?

The study tests the combination of Rituxan (a monoclonal antibody) plus FavId (a vaccine targeting cancer cells) along with GM-CSF (to boost immune response). It aims to see if this combo can trigger an immune reaction against both a protein called KLH and the patient's own tumor markers.See study design

What are the potential side effects?

Possible side effects include reactions at the injection site from vaccines, flu-like symptoms such as fever and chills from Rituxan infusion, blood cell count changes leading to increased infection risk or bleeding problems, liver enzyme alterations indicating potential liver issues.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am able to care for myself and perform daily activities.

Select...

My cancer did not respond or has returned after chemotherapy.

Select...

My condition worsened after initially responding to Rituxan treatment.

Select...

My tumor can be or has been biopsied recently.

Select...

I have not received any treatment for my condition.

Select...

I am 18 years old or older.

Select...

My cancer can be measured after a lymph node biopsy.

Select...

My lymphoma is a low-grade type according to WHO classification.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 8Eligibility criteria met

Find a Location

Who is running the clinical trial?

FavrilleLead Sponsor

5 Previous Clinical Trials

796 Total Patients Enrolled

Media Library

FavId (Cancer Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT00041730 — Phase 2

Non-Hodgkin's Lymphoma Research Study Groups:

Non-Hodgkin's Lymphoma Clinical Trial 2023: FavId Highlights & Side Effects. Trial Name: NCT00041730 — Phase 2

FavId (Cancer Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00041730 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the FDA validated this particular course of treatment?

"As this is a Phase 2 clinical trial, the safety assessment for this treatment plan was rated at level 2. This indicates that there exists some evidence to suggest it is safe but no proof of efficacy yet."

Answered by AI

How many geographical sites are managing this experiment?

"This clinical trial is being held at 15 different medical centres, including the H. Lee Moffitt Cancer Center in Tampa, Tower Hematology Oncology Medical Group in Los Angeles, and University California San Francisco in San Francisco, among others."

Answered by AI

Are there any unfilled positions available to participants in this research?

"Clinicaltrials.gov reveals that this trial, which was originally made available on July 1st 2002 and last edited September 29th 2009, is not currently recruiting patients. However, there are 1778 additional studies actively enrolling participants at the moment."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Rituxan Plus FavId (Idiotype Vaccine) for Low-grade Non-Hodgkin's Lymphoma

2002. "Rituxan Plus FavId (Idiotype Vaccine) for Low-grade Non-Hodgkin's Lymphoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00041730.

All > Hodgkins Lymphoma > Vaccine